Shares of Pulsenmore Ltd. (NASDAQ:PLSM) surged over 200% in premarket trading Wednesday following the company’s announcement of a strategic collaboration with Ouma Health to incorporate Pulsenmore’s FDA-authorized home ultrasound platform into Ouma’s virtual maternity care model.
Under the deal, Ouma Health will be able to use Pulsenmore’s at-home ultrasound system as part of its virtual prenatal care workflows nationwide. The companies say clinicians will be able to extend prenatal ultrasound monitoring into patients’ homes while maintaining a continuous connection between expectant mothers and their clinical teams.
The partnership represents a notable expansion of Pulsenmore’s footprint in the U.S. maternal health market, offering a route to integrate its technology into an established virtual care platform that serves expectant mothers across the country.
In a comment included with the announcement, Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, emphasized the opportunity presented by the collaboration. "By partnering with Ouma Health, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care," he said, adding that 35% of U.S. counties are classified as maternal care deserts.
Ouma Health’s CEO, Dr. Sina Haeri, described the company’s patient base as often facing significant geographic and logistical barriers to prenatal care. He said Pulsenmore’s technology provides a way to deliver more of the prenatal monitoring experience into the home while keeping patients connected to a clinical team that can review data and guide next steps.
The stated aims of the collaboration include delivering care to underserved patients and generating insights to support potential future expansion with healthcare systems, maternity care providers, and payer organizations. Pulsenmore, headquartered in Ramat Gan, Israel, is identified as a pioneer in home ultrasound technology and the company also trades on the Tel Aviv Stock Exchange under the ticker PLSM.
The market reaction was immediate, with the company’s shares rising sharply in premarket trading. The announcement highlights the intersection of home medical devices, virtual care delivery and maternal health, and it underscores the interest among investors in companies that bridge diagnostic technology and telemedicine platforms.
Context and implications
While the collaboration is presented as a means to expand access to prenatal monitoring, the companies frame the agreement as an initial step toward gathering clinical and operational insights that could support broader partnerships with institutional healthcare actors and payers.